Mubadala Bio, a wholly owned subsidiary of Mubadala Investment Company, launched in 2025, is a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond.

Operating across two core verticals — Integrated Biopharma and Pharma Logistics — Mubadala Bio focuses on local manufacturing and distribution to ensure the availability of the most critical and in-demand medical therapies.

Mubadala Bio's integrated portfolio includes 10 facilities spans across Asia, Africa and Europe (with 6 located within the Emirates), serving over 100 countries.

Across these sites, the cumulative manufacturing capacity of its facilities exceeds 2.5 billion tablets and capsules, 120 million IVs and injectables annually, and spans 110,000 square metres of plant area - enabling the production and global distribution of more than 10,000 products.

Mubadala Bio’s portfolio focuses on key therapy areas that address some of the world’s most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support, and complementary medicine.

By forging long-term strategic partnerships with global industry leaders and top-tier academic institutions, Mubadala Bio is accelerating biopharma innovation and local manufacturing, cultivating world-class talent and driving accelerated advancements.